Author:
Bauml Joshua,Mick Rosemarie,Zhang Yu,Watt Christopher D.,Vachani Anil,Aggarwal Charu,Evans Tracey,Langer Corey
Funder
Pennsylvania Department of Health
GO grant
Subject
Cancer Research,Pulmonary and Respiratory Medicine,Oncology
Reference31 articles.
1. Cancer statistics, 2012;Siegel;CA Cancer J Clin,2012
2. Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study;Zhou;Lancet Oncol,2011
3. Biomarker analyses and final overall survival results from a phase III, randomized, open-label, first-line study of gefitinib versus carboplatin/paclitaxel in clinically selected patients with advanced non-small-cell lung cancer in Asia (IPASS);Fukuoka;J Clin Oncol: Offi J Am Soc Clin Oncol,2011
4. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib;Lynch;N Engl J Med,2004
5. A randomized phase III study of gefitinib versus standard chemotherapy (gemcitabine plus cisplatin) as a first-line treatment for never-smokers with advanced or metastatic adenocarcinoma of the lung;Lee,2009
Cited by
79 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献